Details for Patent: 9,732,062

Which drugs does patent 9,732,062 protect, and when does it expire?

Patent 9,732,062 protects IDHIFA and is included in one NDA.

This patent has fifty-six patent family members in thirty-eight countries.

Summary for Patent: 9,732,062

Title:	Therapeutically active compounds and their methods of use
Abstract:	Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Inventor(s):	Giovanni Cianchetta, Byron Delabarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
Assignee:	Wuxi Apptec Co Ltd , Servier Pharmaceuticals LLC
Application Number:	US13/735,467
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,732,062

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No				Y
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes				Y

International Family Members for US Patent 9,732,062

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	090411
Australia	2013207289
Australia	2017265096
Brazil	112014016805